NCT03300037

Brief Summary

The HYPNOS study is an acute feasibility study to validate a new device for automatic detection and treatment of sleep apnea syndrome. The system is known as the PASITHEA system and it will perform the following tasks:

  • Detect apneas and hypopneas in real time, based on physiological signals acquired with a cardiorespiratory holter (nasal air flow, heart rate and blood oxygen saturation (SaO2))
  • Upon detection of apnea or hypopnea events, trigger kinesthetic stimulation of mechanoreceptors of the skin close to the mastoid bone The primary objective is to verify that the PASITHEA system is able to detect apneas and hypopneas reliably. The main secondary objective of the study is to assess the effect of kinesthetic stimulation on reducing the number of sleep respiratory disorders. Another objective of the study is to verify the safety of the PASITHEA system.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
46

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Sep 2014

Shorter than P25 for all trials

Geographic Reach
1 country

5 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2014

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 16, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 16, 2015

Completed
2.3 years until next milestone

First Submitted

Initial submission to the registry

August 3, 2017

Completed
2 months until next milestone

First Posted

Study publicly available on registry

October 3, 2017

Completed
Last Updated

October 3, 2017

Status Verified

October 1, 2017

Enrollment Period

8 months

First QC Date

August 3, 2017

Last Update Submit

October 2, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • Performance of real-time detector of apnea and hypopnea: sensitivity and positive predictive value of the detector will be calculated when comparing automatically detected respiratory events to gold-standard PSG scoring of apnea/hypopnea events.

    During the night of the recording, the PASITHEA system and the PSG will be positioned in parallel. PSG-scored events will be matched with the output of the real-time detector: a true positive event is defined as an event detected less than 10 seconds before or within the duration of a PSG-annotated events. Apneas detected as hypopneas (and reciprocally) will be regarded as true positives. Sensitivity and positive predictive value will be calculated as per conventional definintion and the 9% confidence interval will be calculated using the Wilson score.

    1 night

Secondary Outcomes (1)

  • Safety: number of adverse events with treatment ON or OFF as defined by ISO 14155, rev 2011

    1 night

Interventions

The kinesthetic actuator is placed on the skin near the ear and emits vibrations.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Severe untreated obstructive SAS patients

You may qualify if:

  • above 18 years.
  • Patient with diagnosed severe obstructive sleep apnea syndrome (AHI \> 30/h and \> 80% of obstructive events diagnosed on polysomnography or polygraphy performed less than 6 months ago )
  • Patient free from CPAP treatment or any other SAS treatment for at least 3 months
  • Patient with stable psychotropic medication since the diagnostic polysomnography or polygraphy exam
  • Patient has signed the informed consent

You may not qualify if:

  • Patients sleeping less than 4 hours per night
  • Patients suffering from respiratory failure or periodic breathing (cheynes stokes)
  • Obese patient (BMI\>40kg/m2)
  • Diabetic patient with autonomic dysfunction
  • Vulnerable patient in accordance with article L1121-6 of CSP
  • Patient with progressive malignant pathology
  • Patient already involved in another clinical study that could affect the result of this study
  • Pregnant patient

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (5)

CHU Angers

Angers, 49000, France

Location

Laboratoire du sommeil et d'EFCR; Hopital Michallon

Grenoble, 38043, France

Location

CHU Montpellier

Montpellier, France

Location

CHU Rennes

Rennes, France

Location

University Hospital Tours

Tours, 37 044, France

Location

MeSH Terms

Conditions

Sleep Apnea, Obstructive

Condition Hierarchy (Ancestors)

Sleep Apnea SyndromesApneaRespiration DisordersRespiratory Tract DiseasesSleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 3, 2017

First Posted

October 3, 2017

Study Start

September 1, 2014

Primary Completion

April 16, 2015

Study Completion

April 16, 2015

Last Updated

October 3, 2017

Record last verified: 2017-10

Data Sharing

IPD Sharing
Will not share

Locations